NxStage Medical (NXTM)

Add to Watchlists Create an Alert
13.60 -0.14  -1.02%   NASDAQ May 23, 8:00PM BATS Real time Currency in USD

NxStage Medical R&D Expense Quarterly:

5.108M for March 31, 2013
View Full Chart

NxStage Medical R&D Expense Quarterly Chart

    NxStage Medical Historical R&D Expense Quarterly Data

    Pro Data Export
    Dates:  to
    Viewing 1 of 1   First  Previous First    Next  Last   Last

    There is no data for the selected date range.

    Data for this Date Range  
    March 31, 2013 5.108M
    Dec. 31, 2012 4.69M
    Sept. 30, 2012 4.274M
    June 30, 2012 4.25M
    March 31, 2012 3.897M
    Dec. 31, 2011 3.743M
    Sept. 30, 2011 3.388M
    June 30, 2011 3.589M
    March 31, 2011 3.717M
    Dec. 31, 2010 3.531M
    Sept. 30, 2010 3.132M
    June 30, 2010 3.202M
    March 31, 2010 3.035M
    Dec. 31, 2009 2.434M
    Sept. 30, 2009 2.707M
    June 30, 2009 2.271M
    March 31, 2009 2.402M
       
    Dec. 31, 2008 2.416M
    Sept. 30, 2008 1.986M
    June 30, 2008 2.362M
    March 31, 2008 Go Pro
    Dec. 31, 2007 Go Pro
    Sept. 30, 2007 Go Pro
    June 30, 2007 Go Pro
    March 31, 2007 Go Pro
    Dec. 31, 2006 Go Pro
    Sept. 30, 2006 Go Pro
    June 30, 2006 Go Pro
    March 31, 2006 Go Pro
    Dec. 31, 2005 Go Pro
    Sept. 30, 2005 Go Pro
    June 30, 2005 Go Pro
    Dec. 31, 2004 Go Pro
    Sept. 30, 2004 Go Pro

    About R&D Expense

    R&D expenses are a line item from many companies' income statements.

    R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

    Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

    An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
    Learn More

    Get data for

    NXTM R&D Expense Quarterly Benchmarks

    Companies
    Covidien 162.00M
    Derma Sciences 2.569M
    AngioDynamics 5.793M

    NXTM R&D Expense Quarterly Rankings

    Overall 89th percentile
    817 of 8006
    Sector 66th percentile
    230 of 686 in Healthcare
    Industry 70th percentile
    22 of 74 in Medical Instruments & Supplies

    NXTM R&D Expense Quarterly Range, Past 5 Years

    Minimum 1.986M Sep 2008
    Maximum 5.108M Mar 2013
    Average 3.307M